ECM
APGE icon

ExodusPoint Capital Management’s Apogee Therapeutics APGE Stock Holding History

ExodusPoint Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,535
Closed -$1.49M – 1515
2025
Q3 		$1.49M Buy
+37,535
New +$1.43M 0.02% 829

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ExodusPoint Capital Management's APGE Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 37,535 shares — an estimated $1.49M sold.

ExodusPoint Capital Management first reported a position in APGE in Q3 2025 and held it in 1 quarter. The position peaked at $1.49M in Q3 2025. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 37,535 Apogee Therapeutics shares in Q4 2025, an estimated $1.49M.
  • ExodusPoint Capital Management first reported a position in Apogee Therapeutics in Q3 2025 and held it in 1 quarter.
  • ExodusPoint Capital Management's Apogee Therapeutics position peaked at $1.49M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.